Executives On The Move: New CSOs at Alize and Innovio, Plus Oncology Head at Nektar Therapeutics
Executive Summary
Ipsen VP, Endocrinology is now CSO at metabolic and rare disease Alize Pharma, and cancer and infectious disease firm Innovio Pharmaceuticals promotes R&D leader to CSO. Plus new Head, Oncology at Nektar Therapeutics to lead area strategy.
You may also be interested in...
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.
Pipeline Watch: Six Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.